ロード中...
FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation
On November 6, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of adult patients with Erdheim‐Chester disease (ECD) with BRAFV600 mutation. ECD is a type of histiocytosis, a rare disorder characterized by an abnormal accumulation and behavi...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6292556/ https://ncbi.nlm.nih.gov/pubmed/30120160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0295 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|